R N Formica
Overview
Explore the profile of R N Formica including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levitsky J, Formica R
Am J Transplant
. 2017 Sep;
17(11):2988.
PMID: 28858416
No abstract available.
2.
Levitsky J, Formica R, Bloom R, Charlton M, Curry M, Friedewald J, et al.
Am J Transplant
. 2017 May;
17(11):2790-2802.
PMID: 28556422
The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection....
3.
Newell K, Formica R, Gill J, Schold J, Allan J, Covington S, et al.
Am J Transplant
. 2016 Dec;
17(4):901-911.
PMID: 27997071
Thirteen percent of individuals of African ancestry express two variant copies of the gene encoding apolipoprotein 1 (APOL1) that has been associated with an increased risk of end-stage renal disease...
4.
Kulkarni S, Kirkiles-Smith N, Deng Y, Formica R, Moeckel G, Broecker V, et al.
Am J Transplant
. 2016 Aug;
17(3):682-691.
PMID: 27501352
We hypothesized that de novo donor-specific antibody (DSA) causes complement-dependent endothelial cell injury in kidney transplants, as assessed by expression of endothelial cell-associated transcripts (ENDATs), that may be attenuated through...
5.
Kulkarni S, Thiessen C, Formica R, Schilsky M, Mulligan D, DAquila R
Am J Transplant
. 2016 Aug;
16(12):3385-3391.
PMID: 27500361
Transplant professionals recognize that the long-term follow-up of living organ donors is a priority, yet there has been no implemented solution to this problem. This critical gap is essential, because...
6.
Stewart D, Kucheryavaya A, Klassen D, Turgeon N, Formica R, Aeder M
Am J Transplant
. 2016 Mar;
16(6):1834-47.
PMID: 26932731
After over a decade of discussion, analysis, and consensus-building, a new kidney allocation system (KAS) was implemented on December 4, 2014. Key goals included improving longevity matching between donor kidneys...
7.
Newell K, Formica R, Gill J
Am J Transplant
. 2015 Dec;
16(1):29-32.
PMID: 26639020
Recent studies have highlighted the need for better understanding of the long-term health outcomes of living donors. Barriers to establishment of a dedicated long-term donor follow-up data system in the...
8.
Formica R, Aeder M, Boyle G, Kucheryavaya A, Stewart D, Hirose R, et al.
Am J Transplant
. 2015 Nov;
16(3):758-66.
PMID: 26603142
The introduction of the Mayo End-Stage Liver Disease score into the Organ Procurement and Transplantation Network (OPTN) deceased donor liver allocation policy in 2002 has led to a significant increase...
9.
Hricik D, Augustine J, Nickerson P, Formica R, Poggio E, Rush D, et al.
Am J Transplant
. 2015 Aug;
15(12):3166-73.
PMID: 26226830
Previous studies suggest that quantifying donor-reactive memory T cells prior to kidney transplantation by interferon gamma enzyme-linked immunosorbent spot assay (IFNγELISPOT) can assist in assessing risk of posttransplant allograft injury....
10.
Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury
Hricik D, Nickerson P, Formica R, Poggio E, Rush D, Newell K, et al.
Am J Transplant
. 2013 Aug;
13(10):2634-44.
PMID: 23968332
Noninvasive biomarkers are needed to assess immune risk and ultimately guide therapeutic decision-making following kidney transplantation. A requisite step toward these goals is validation of markers that diagnose and/or predict...